Isa Mambetsariev

1.7k total citations
70 papers, 1.1k citations indexed

About

Isa Mambetsariev is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Isa Mambetsariev has authored 70 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Isa Mambetsariev's work include Lung Cancer Treatments and Mutations (36 papers), Lung Cancer Research Studies (16 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Isa Mambetsariev is often cited by papers focused on Lung Cancer Treatments and Mutations (36 papers), Lung Cancer Research Studies (16 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Isa Mambetsariev collaborates with scholars based in United States, India and China. Isa Mambetsariev's co-authors include Ravi Salgia, Prakash Kulkarni, Rebecca Pharaon, Arin Nam, Martin Sattler, Erminia Massarelli, Arya Amini, Yufeng Tian, Anna A. Birukova and Marianna Koczywas and has published in prestigious journals such as Journal of Clinical Oncology, Bioinformatics and PLoS ONE.

In The Last Decade

Isa Mambetsariev

62 papers receiving 1.1k citations

Peers

Countries citing papers authored by Isa Mambetsariev

Since Specialization

Citations

This map shows the geographic impact of Isa Mambetsariev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isa Mambetsariev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isa Mambetsariev more than expected).

Fields of papers citing papers by Isa Mambetsariev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isa Mambetsariev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isa Mambetsariev. The network helps show where Isa Mambetsariev may publish in the future.

Co-authorship network of co-authors of Isa Mambetsariev

This figure shows the co-authorship network connecting the top 25 collaborators of Isa Mambetsariev. A scholar is included among the top collaborators of Isa Mambetsariev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isa Mambetsariev. Isa Mambetsariev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition 2025 ·Current Oncology ·(unknown), Isa Mambetsariev, Siddhika Pareek, (unknown), (unknown), (unknown), (unknown), Leonidas Arvanitis, Débora S. Bruno, Stacy W. Gray, Ravi Salgia	0
2	The clinical utility of a circulating tumor cell based cerebrospinal fluid assay in the diagnosis and molecular analysis of leptomeningeal disease in patients with metastatic non-small cell lung cancer. 2024 ·Journal of Clinical Oncology ·Ramya Muddasani, (unknown), (unknown), Isa Mambetsariev, Erminia Massarelli, Michelle Afkhami, Ravi Salgia, Jyoti Malhotra	1
3	Targeting CNS Metastases in Non–Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers 2024 ·JAMA Oncology ·Jyoti Malhotra, Isa Mambetsariev, (unknown), (unknown), Arin Nam, (unknown), Bihong T. Chen, (unknown), Arya Amini, Rimas V. Lukas, Ravi Salgia	2
4	Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy 2023 ·Frontiers in Oncology ·(unknown), Isa Mambetsariev, Kun‐Han Lu, Chi Wah Wong, (unknown), (unknown), (unknown), (unknown), Leonidas Arvanitis, (unknown), Arya Amini, Marianna Koczywas, Erminia Massarelli, Moom R. Roosan, Ravi Salgia	9
5	Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma 2023 ·Molecular Case Studies ·Diogo Moniz‐Garcia, Isa Mambetsariev, (unknown), Daniel Schmolze, Michelle Afkhami, (unknown), Pauline Kim, (unknown), (unknown), (unknown), Yuman Fong, Ravi Salgia	1
6	Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status 2023 ·Brain Sciences ·Bihong T. Chen, (unknown), (unknown), (unknown), Russell C. Rockne, Stephanie Yoon, Isa Mambetsariev, Ebenezer Daniel, Ravi Salgia	2
7	A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine 2023 ·Journal of Clinical Medicine ·Martin Sattler, Isa Mambetsariev, (unknown), (unknown), (unknown), Nagarajan Vaidehi, Evan Pisick, Tamara Mirzapoiazova, (unknown), (unknown), Sunil Sharma, Ravi Salgia	9
8	Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer 2023 ·Cancers ·(unknown), Arya Amini, Isa Mambetsariev, (unknown), (unknown), Colton Ladbury, Ravi Salgia	16
9	Clinical Network Systems Biology: Traversing the Cancer Multiverse 2023 ·Journal of Clinical Medicine ·Isa Mambetsariev, (unknown), Stephen B. Gruber, (unknown), (unknown), Pauline Kim, Priya Vishnubhotla, Jianjun Chen, Prakash Kulkarni, Ravi Salgia	5
10	Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report 2021 ·Clinical Lung Cancer ·Thomas C. Waddington, Isa Mambetsariev, Rebecca Pharaon, (unknown), (unknown), (unknown), (unknown), Stacy W. Gray, Ravi Salgia	5
11	The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) 2021 ·Cell Reports Medicine ·Ravi Salgia, Rebecca Pharaon, Isa Mambetsariev, Arin Nam, Martin Sattler	104
12	Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer 2021 ·CHEST Journal ·Moom R. Roosan, Isa Mambetsariev, Rebecca Pharaon, (unknown), Hatim Husain, Karen L. Reckamp, Marianna Koczywas, Erminia Massarelli, Andrea H. Bild, Ravi Salgia	27
13	Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer 2021 ·Frontiers in Oncology ·Bihong T. Chen, (unknown), Ningrong Ye, Isa Mambetsariev, (unknown), Chi Wah Wong, Zikuan Chen, Russell C. Rockne, Rivka R. Colen, Andrei I. Holodny, Sagus Sampath, Ravi Salgia	38
14	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy 2021 ·Journal of Thoracic Oncology ·Jacqueline V. Aredo, Isa Mambetsariev, Jessica A. Hellyer, Arya Amini, Joel W. Neal, Sukhmani K. Padda, Caroline E. McCoach, Jonathan W. Riess, Elwyn C. Cabebe, Jarushka Naidoo, (unknown), Ravi Salgia, Billy W. Loo, Maximilian Diehn, Summer S. Han, Heather A. Wakelee	86
15	Co-stimulatory and co-inhibitory Immune Markers in Solid Tumors With MET Alterations 2020 ·Future Science OA ·Karen L. Reckamp, Jasmine A. McQuerry, Isa Mambetsariev, Rebecca Pharaon, Susan E. Yost, (unknown), Tamara Mirzapoiazova, Raju Pillai, Leonidas Arvanitis, Ziad U. Khan, Marwan Fakih, Yuan Yuan, Marianna Koczywas, Erminia Massarelli, Prakash Kulkarni, Sumanta K. Pal, Martin Sattler, (unknown), Ravi Salgia	1
16	Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases 2020 ·Magnetic Resonance Imaging ·Bihong T. Chen, (unknown), Ningrong Ye, Isa Mambetsariev, Ebenezer Daniel, (unknown), Chi Wah Wong, Russell C. Rockne, Rivka R. Colen, Andrei I. Holodny, Sagus Sampath, Ravi Salgia	41
17	Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas 2020 ·iScience ·Saumya Srivastava, Ka Ming Pang, Mari Iida, Michael S. Nelson, Jiayi Liu, Arin Nam, Jiale Wang, Isa Mambetsariev, Raju Pillai, Atish Mohanty, (unknown), Amita Behal, Prakash Kulkarni, Deric L. Wheeler, Ravi Salgia	10
18	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors 2020 ·Lung Cancer ·Dan Zhao, Isa Mambetsariev, Haiqing Li, Chen Chen, (unknown), (unknown), Prakash Kulkarni, Yan Xing, Peter P. Lee, Andrea Bild, Erminia Massarelli, Marianna Koczywas, Karen L. Reckamp, Ravi Salgia	9
19	Attenuation of Lipopolysaccharide-Induced Lung Vascular Stiffening by Lipoxin Reduces Lung Inflammation 2014 ·American Journal of Respiratory Cell and Molecular Biology ·Fanyong Meng, Isa Mambetsariev, Yufeng Tian, Yvonne Beckham, Angelo Y. Meliton, Alan R. Leff, Margaret L. Gardel, Michael J. Allen, Konstantin G. Birukov, Anna A. Birukova	37
20	Role of microtubules in attenuation of PepG-induced vascular endothelial dysfunction by atrial natriuretic peptide 2014 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Yufeng Tian, Isa Mambetsariev, Nicolene Sarich, Fanyong Meng, Anna A. Birukova	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact